Abstract-Heart failure is the leading cause of mortality in patients with transfusional iron (Fe) overload in which myocardial iron uptake ensues via a transferrin-independent process. We examined the ability of L-type Ca 2ϩ channel modifiers to alter Fe 2ϩ uptake by isolated rat hearts and ventricular myocytes. Perfusion of rat hearts with 100 nmol/L 59
Abstract-Heart failure is the leading cause of mortality in patients with transfusional iron (Fe) overload in which myocardial iron uptake ensues via a transferrin-independent process. We examined the ability of L-type Ca 2ϩ channel modifiers to alter Fe 2ϩ uptake by isolated rat hearts and ventricular myocytes. Perfusion of rat hearts with 100 nmol/L 59 Fe 2ϩ and 5 mmol/L ascorbate resulted in specific 59 Fe 2ϩ uptake of 20.4Ϯ1.9 ng of Fe per gram dry wt. Abolishing myocardial electrical excitability with 20 mmol/L KCl reduced specific 59 Fe 2ϩ uptake by 60Ϯ7% (PϽ0.01), which suggested that a component of myocardial Fe 2ϩ uptake depends on membrane voltage. Accordingly, 59 Fe 2ϩ uptake was inhibited by 10 mol/L nifedipine (45Ϯ12%, PϽ0.02) and 100 mol/L Cd 2ϩ (86Ϯ3%; PϽ0.001) while being augmented by 100 nmol/L Bay K 8644 (61Ϯ18%, PϽ0.01) or 100 nmol/L isoproterenol (40Ϯ12%, PϽ0.05). By contrast, uptake of 100 nmol/L ferric iron ( 59 2ϩ enhanced Ca 2ϩ current amplitude and slowed inactivation rates, which was consistent with Fe 2ϩ entry into the cell, whereas higher Fe 2ϩ levels caused dose-dependent decreases in peak current. Fe 3ϩ had no effect on current amplitude or decay. Combined, our data suggest that myocardial Fe 2ϩ uptake occurs via L-type Ca 2ϩ channels and that blockade of these channels might be useful in the treatment of patients with excessive serum iron levels. (Circ Res. 1999;84:1302-1309.) Key Words: iron overload Ⅲ channels Ⅲ heart failure Ⅲ permeability Ⅲ Ca 2ϩ I ron is essential for cellular metabolism and enzyme function. Normally, tissue levels of iron are precisely regulated and stored as a ferritin complex, thereby minimizing the potential toxic effects of catalytically active iron. 1 However, elevations in serum iron occur commonly and are associated with a number of disease conditions. For example, acute iron poisoning is the most common cause of overdose mortality in young children 2 and often results in myocardial dysfunction. 3 On the other hand, chronic elevations of serum iron are associated with a number of disease conditions, including cardiomyopathy, diabetes mellitus, hypopituitarism, and liver cirrhosis. 4 -6 Iron overload cardiomyopathy is the most common cause of heart failure in young adults and is often associated with arrhythmias. 7 It generally results from primary or secondary hemochromatosis. 7 Primary (or hereditary) hemochromatosis is an autosomal recessive disorder that results from mutations in the histocompatibility antigen HLA-A 8 and afflicts Ϸ10% of people from European extraction. 9 Secondary hemochromatosis is the most common single gene disorder in humans 10 ; it causes major thalassemic syndromes and sideroblastic anemias associated with ineffective erythropoietic activity and parenchymal iron overload. 9, 11 In addition, iron overload in these patients is often compounded by additional iron loads that result from chronic blood transfusions. 11 Currently, no satisfactory therapies exist for the treatment of iron overload disorders. Iron chelators have aided the long-term survival of iron-overload patients 12 and reduce the incidence of cardiac dysfunction. 13 However, patient compliance is poor with deferoxamine mesylate, 14 and recent evidence suggests that the oral chelator deferiprone is ineffective in thalassemic patients and may promote hepatic fibrosis. 15 Although chelation treatment improves survival, 12 these patients are still at risk for developing late iron-induced cardiomyopathy. 7 Therefore, understanding the mechanisms involved in iron accumulation in the heart and other tissues may prove useful for the development of new treatment strategies in iron-overload patients.
In most cells, iron uptake is mediated through internalization of the transferrin-iron complex bound to high-affinity membrane receptors. 16 A second mechanism of iron uptake occurs through a transferrin-independent process. This nontransferrin-bound iron (NTBI) transport process is considered to have a minor role in iron uptake under normal physiological conditions but becomes the primary uptake mechanism when serum iron is severely elevated (eg, primary and secondary hemochromatosis). Under these conditions, iron saturation of transferrin and reductions in the number of transferrin receptors occur, which results in excessive transferrin-independent iron uptake via an unknown transporter pathway. 16, 17 NTBI uptake has been demonstrated in a number of mammalian cells, including cardiac myocytes. 18, 19 It is calcium-dependent and can be enhanced by prior iron loading of the cell. 20, 21 Of importance to our studies, it has been shown that a critical step in NTBI uptake is the reduction of ferric iron (Fe 3ϩ ) to the ferrous state (Fe 2ϩ ) by a membrane-associated ferrireductase. 21 In the present study, we demonstrate that a significant component of myocardial uptake of reduced iron (ie, Fe 2ϩ ) is dependent on the electrical excitability of the heart and can be modulated by agents and interventions that affect the L-type Ca 2ϩ channel activity. In addition, we show that Fe 2ϩ permeates Ca 2ϩ channels at high concentrations and can alter channel kinetics at lower concentrations. Our results suggest that L-type Ca 2ϩ channels might contribute significantly to iron uptake by the heart and has many of the properties associated with the unknown NTBI uptake pathway.
Materials and Methods

Fe Uptake in Isolated Perfused Hearts
Hearts were rapidly excised from heparinized and anesthetized (sodium pentobarbital, 75 mg/kg) male Sprague-Dawley rats (Charles River, Montreal, Canada; 200 -250 g) and mounted for perfusion using the Langendorff technique. Isolated hearts were perfused with Tyrode's solution (8 59 Fe from the vascular lumen. To reduce nonspecific 59 Fe 2ϩ binding to the perfusion system, 10 mol/L FeCl 2 or FeCl 3 was included in the perfusion solution. Hearts were blotted dry, and atrial and connective tissues were removed; 59 Fe 2ϩ uptake was determined by gamma counting. Nonspecific 59 Fe 2ϩ uptake was calculated by subtracting the radioactivity measured in the presence of 1 mmol/L FeCl 2 . Electrical activity was arrested in hearts with 20 mmol/L KCl. Nifedipine (10 mol/L; Sigma Chemical Co), (Ϫ)Bay K 8644 (100 nmol/L; Research Biochemicals International), or isoproterenol (100 nmol/L; Sigma) was added to the perfusion solution. Stock nifedipine (10 mmol/L) and (Ϫ)Bay K 8644 (1 mmol/L) were dissolved in ethanol. The final concentration of ethanol (0.1%) had no effect on 59 Fe 2ϩ uptake.
Electrophysiology
Whole-cell Ca 2ϩ currents were recorded at room temperature from enzymatically isolated rat cardiac ventricular myocytes 22 using the patch-clamp technique 23 . At the end of the experiments, 20 mol/L nitrendipine was used to determine dihydropyridine-sensitive currents. Nitrendipine was used for these experiments instead of nifedipine to minimize photoinactivation. 24 
Data Analysis
Data acquisition and analysis was performed using custom written and Origin software (MicroCal, Inc). The dose-response relationship was fit with a Hill equation:
n /IC 50 n ), where IC 50 is the half-maximal inhibitory concentration of Fe 2ϩ and n is the Hill coefficient. Data are presented as the meanϮSEM. Statistical analysis was performed by use of a 1-way ANOVA followed by a multiple comparison testing (Student-Newman-Keuls; (SPSS 7.5; SPSS). A P value Ͻ0.05 was used to denote statistical differences between groups.
Results
Iron Uptake in Isolated, Perfused Hearts
Iron uptake in most mammalian cells is mediated primarily through a transferrin-dependent process, but under conditions of iron overload, NTBI uptake becomes the predominant mode of iron uptake. 18, 20 In rat myocardium, NTBI uptake can exceed the transferrin-dependent pathways by 300-fold. 18 Because the redox state of iron is critical in NTBI uptake and 59 Fe 2ϩ uptake of isolated perfused rat hearts is voltage-dependent. Hearts were perfused with 59 Fe 2ϩ (100 nmol/L) for 15 minutes followed by a 10-minute washout period in the absence and presence of KCl (20 mmol/L), nifedipine (1 or 10 mol/L), Cd 2ϩ (100 mol/L), Bay K 8644 (100 nmol/L), or isoproterenol (100 nmol/L). 59 Fe uptake was measured from ventricular tissue and normalized to dry wt. Data represent the meanϮSEM of 6 to 8 hearts. *PϽ 0.05, **PϽ 0.01.
Fe
2ϩ is the primary ionic species translocated across the cell membrane, 21, 25 we initially examined iron uptake into myocardium by perfusing isolated rat hearts (Figure 1 ) with 100 nmol/L 59 Fe 2ϩ . This concentration is well below the plasma levels of NTBI measured in patients with hemochromatosis (ie, 1 to 20 mol/L; References 26 -28) or in some children after acute iron poisoning (ie, Ͼ1 mmol/L; Reference 29). Perfusion of rat hearts for 15 minutes resulted in specific 59 Fe 2ϩ uptake of 20.4Ϯ1.9 ng Fe per g of dry wt (nϭ7). Electrically arresting the hearts with 20 mmol/L KCl reduced 59 Fe 2ϩ uptake to 8.1Ϯ1.3 ng Fe per g dry wt (nϭ8; PϽ0.01; Figure 1 59 Fe 2ϩ uptake. Consistent with our expectations, 10 mol/L nifedipine, an L-type Ca 2ϩ channel antagonist, 35 suppressed myocardial contractility in the isolated perfused rat hearts and decreased 59 Fe 2ϩ uptake to 11.2Ϯ2.5 ng Fe per g dry wt (nϭ6, PϽ0.02, Figure 1 ), a level not significantly different from KCl-arrested hearts (PϾ0.26). A lower concentration of nifedipine (1 mol/L) produced a more modest reduction in 59 Fe 2ϩ uptake (17.9Ϯ0.7 ng Fe per g dry wt, nϭ6). Conversely, augmenting Ca 2ϩ channel activity with the specific L-type Ca 2ϩ channel agonist 35, 36 (Ϫ)Bay K 8644 significantly increased 59 Fe 2ϩ uptake to 32.9Ϯ3.7 ng Fe per g dry wt (nϭ7; PϽ0.01), which is 2.3-fold greater than the nifedipine-sensitive component. Because L-type Ca 2ϩ channel activity is enhanced by ␤-adrenergic receptor activation, 37, 38 100 nmol/L isoproterenol was added to the perfusion media. This agent caused a significant 40% enhancement of 59 Fe 2ϩ uptake (28.6Ϯ2.5 ng Fe per g of wt; nϭ6, PϽ0.05). Next, we examined the effects of the inorganic divalent cation Cd 2ϩ , which blocks L-type Ca 2ϩ channels. 31, 34 As shown in Figure 1 , 100 mol/L Cd 2ϩ markedly inhibited 59 Fe 2ϩ uptake by 86% (2.9Ϯ0.6 ng of Fe per g dry wt, nϭ6; PϽ0.001). The inhibition of 59 Fe 2ϩ uptake by Cd 2ϩ was significantly greater (PϽ0.01) than with KCl or nifedipine, suggesting that transporters other than L-type Ca 2ϩ channels may be involved in myocardial iron uptake. This is not unexpected because Cd 2ϩ interferes with numerous other membrane transporters including iron transporters. 21, 39 In contrast to these findings, uptake of radioactive oxidized iron ( 59 Fe 3ϩ ) by the perfused rat hearts (1.4Ϯ0.3 ng Fe per g dry wt, nϭ4) was 15-fold less than 59 Fe 2ϩ uptake (PϽ0.001). These results are consistent with previous publications showing that ferrous iron (Fe 2ϩ ) is the primary species entering the heart via the NTBI mechanism. 21, 25 Fe 2؉ Permeation of L-Type Ca 2؉ Channels
The dependence of 59 Fe 2ϩ uptake on cellular excitability and agents that affect L-type Ca 2ϩ channel function led us to examine the interaction of Fe 2ϩ with the cardiac L-type Ca nitrendipine completely blocked all inward current ( Figure  2C ). The nitrendipine-sensitive Fe 2ϩ currents showed little current inactivation ( Figure 2D ). In addition, activation of the nitrendipine-sensitive Fe 2ϩ currents was shifted by 16Ϯ2 mV (nϭ8), resulting in a large rightward shift in the peak of the current-voltage relationship with no measurable change in the reversal potential ( Figure 2E ). The depolarizing shift in the voltage dependence of activation most probably resulted from the screening of negative surface charges caused by the higher concentration of divalent cation concentration in the external media (15 Figure 3A and 3C). At higher concentrations, Fe 2ϩ reduced the peak I Ca in a dose-dependent manner, with an IC 50 of 2.1 mmol/L ( Figure  3A and 3C), which is remarkably similar to previous estimates of 2.7 mmol/L, determined in single-channel studies. 30 Concomitant with the reduction in peak I Ca , current decay was slowed in a dose-dependent manner ( Figure 3B ). To quantify the effects of Fe 2ϩ on current inactivation, the fraction of the current at the end of the 200-millisecond depolarization to the peak current at 0 mV (r 200 ) was plotted as a function of the Fe 2ϩ concentration ( Figure 4A ). 45, 46 In the absence of Fe 2ϩ , r 200 was 0.11Ϯ0.02 (nϭ8), similar to previously reported values. 45 In the presence of 500 mol/L Fe 2ϩ , r 200 significantly increased to 0.20Ϯ0.02 (nϭ5; PϽ 0.05) and to 0.48Ϯ0.04 at 4 mmol/L Fe 2ϩ (nϭ5; PϽ0.01). These alterations in inactivation kinetics might affect the net influx of Ca 2ϩ into the cell and intracellular Ca 2ϩ concentrations despite reductions in the peak current. Indeed, the time integral of the current traces in Figure 4B reveal that the total charge influx increased from 0.38Ϯ0.03 pC/pF in control cells to 0.59Ϯ0.07 pC/pF (PϽ0.01) in the presence of 500 mol/L Fe 2ϩ . The time integral of the currents gradually decreased at Fe 2ϩ concentrations Ͼ2 mmol/L ( Figure 4B ). Thus, Fe 2ϩ slows the decay of the Ca 2ϩ current in a dosedependent manner, and at concentrations Ͻ500 mol/L, it increases Ca 2ϩ influx through the channel. The effects of iron on the L-type Ca 2ϩ channel were specific for the reduced form of iron (ie, Fe Figure 5B and more importantly did not affect current decay ( Figure 5A ). These data suggest that uptake of myocardial iron via the L-type Ca , permeation. The modulation of L-type Ca 2ϩ current by Fe 2ϩ may result from nonspecific modification of the channel protein such as sulfhydryl oxidation due to Fe 2ϩ -dependent free radical production. 1 However, the effects on both peak current and inactivation were reversible when the Fe 2ϩ concentration was changed from 500 mol/L to 2 mmol/L and then back to 500 mol/L (Figure 6 ). These results suggest that irreversible modification of the channel protein did not occur and therefore is not responsible for the observed effects on channel inactivation.
Discussion
The present study demonstrates that myocardium Fe 2ϩ uptake is inhibited in electrically arrested nonbeating hearts and is modulated by agents that affect L-type Ca 2ϩ channel activity. Iron uptake was inhibited by Ϸ50% in arrested and nifedipine-treated hearts, consistent with the hypothesis that Fe 2ϩ uptake into heart can occur via L-type Ca 2ϩ channels. However, in addition to blocking L-type Ca 2ϩ channels, the high concentrations of nifedipine used in the studies (Figure 1 ) can also inhibit other ion channels [47] [48] [49] that might contribute to 59 Fe 2ϩ uptake, although no previous studies have demonstrated that Fe 2ϩ permeation occurs through these channels. On the other hand, the selective L-type Ca 2ϩ channel agonist Bay K 8644 produced a 2.3-fold increase in the nifedipinesensitive Fe 2ϩ uptake by the heart. Assuming complete block of L-type Ca 2ϩ current by nifedipine (see below), this Bay K 8644 -dependent enhancement of Fe 2ϩ uptake matches the 1.5-to 2-fold increase of current produced by these agents in previous voltage-clamp studies. 35 By contrast, minimal uptake of 59 Fe 3ϩ , which does not permeate L-type Ca 2ϩ channels, occurred in these experiments. Overall, these studies suggest that NTBI (ie, Fe 2ϩ ) uptake into the heart can occur, although probably not exclusively (see below), via L-type Ca 2ϩ channels.
Under our experimental conditions, the extent of Fe 2ϩ blockade by Cd 2ϩ was 2-fold greater than by 10 mol/L nifedipine. The differences between these 2 blockers of L-type Ca 2ϩ channels in our experiments may result at least in part from incomplete blockage of Ca 2ϩ channels by nifedipine, because nifedipine binding to L-type channels is very voltage-dependent. 35, 50 On the other hand, Cd 2ϩ can inhibit many membrane transporters in addition to Ca 2ϩ channels; therefore, it seems likely that a second nifedipine-insensitive iron uptake process exists in the myocardium. One potential candidate transporter is the voltage-dependent divalent-cation transporter (DCT1), which was cloned from rat duodenum and appears to be expressed in heart. 51 However, Cd 2ϩ is actually transported by DCT1, 51 which would not readily explain our observed effects of Cd 2ϩ on Fe 2ϩ uptake. Although both NTBI uptake observed in the present study and DCT1 Fe 2ϩ uptake display similar voltage dependency, it is unknown whether high K ϩ , nifedipine, Bay K 8644, or phosphorylation affect DCT1 transport properties. In contrast to DCT1, voltage-independent Fe 2ϩ uptake has been measured in cultured neonatal rat cardiac myocytes. 25 In these studies, 20 mol/L nifedipine inhibited 20% of 45 Ca 2ϩ uptake in cultured myocytes. 25 This modest effect of nifedipine is not entirely inconsistent with our results because previous studies have demonstrated that L-type Ca 2ϩ channel densities and activity are much lower in cultured neonatal myocytes than adult heart cells. 52 Clearly, additional studies are required to determine whether multiple pathways for NTBI (ie, Fe 2ϩ ) uptake exist in heart and to characterize their relative importance in iron loading.
Our is too slow to be readily detected using electrical recordings 30, 34 under relevant pathophysiological conditions. Previously, it has been suggested that measurement of intracellular accumulation would provide better evidence for the flux of divalent cations, like Fe 2ϩ , through L-type Ca 2ϩ channels. 34 Initially, we attempted to use an optical fluorescence method in isolated cardiac trabeculae and single myocytes. However, these methods were also relatively insensitive partly because redox cycling of iron occurs after Fe 2ϩ enters myocytes (see below), as demonstrated previously by the measurable Fe 3ϩ labile pools in iron-loaded cardiac myocytes. 19 Our radioisotope 59 Fe 2ϩ flux measurements in the whole hearts avoided these problems, thereby allowing estimation of the rate of iron accumulation in heart.
The nifedipine-sensitive component of iron uptake in our Langendorff experiments is remarkably similar to the 14 to 19 pmol ⅐ min Ϫ1 ⅐ g Ϫ1 dry wt of Fe 2ϩ that is predicted from our electrophysiological studies and those of others 30 to enter myocytes via L-type Ca 2ϩ channels. This calculation, outlined below, requires that the relative flux of Fe 2ϩ versus Ca 2ϩ is proportional to the ratio of their maximum current densities (or binding rates) and that binding isotherms adequately describe the dependence of current on the permeant divalent ion concentrations as established previously. 53 Since the Fe 2ϩ current density in rat ventricular myocytes at 0 mV was 0.20 pA/pF with 15 mmol/L Fe 2ϩ and the dissociation constant was 2.1 mmol/L (similar to the 2.7 mmol/L reported previously 30 ), the maximum current (I MAX ) for Fe 2ϩ is estimated to be 0.23 pA/pF. The corresponding I MAX for Ca 2ϩ current density at 0 mV was 38 pA/pF using an estimated IC 50 ϭ14 mmol/L. 53 Thus, the ratio of maximum currents is estimated to be 6.7ϫ10
Ϫ3
, which matches closely the corresponding ratio of 7.6ϫ10 Ϫ3 that is based on the second order binding rate constants (ie, 3.4ϫ10 6 8 myocytes per heart, the dry wt-wet wt ratio is 0.2, and the heart rate is about 200 bpm. In contrast, the predicted flux of Fe 2ϩ at a concentration of 100 nmol/L is 19.1 pmol ⅐ min Ϫ1 ⅐ g Ϫ1 dry wt. Corresponding estimates with the ratios of the second-order rate constants to estimate the Fe 2ϩ flux predict an uptake rate through the L-type Ca 2ϩ channels of 14.3 pmol ⅐ min Ϫ1 ⅐ g Ϫ1 dry wt. The above estimates suggest that sufficient Fe 2ϩ can enter through L-type Ca 2ϩ channels to account for the nifedipinesensitive Fe 2ϩ accumulation observed in our whole heart experiments, provided that extrusion is relatively slow. Is this, in fact, likely to be the case? Previous studies have established that in conditions of iron overload, NTBI entry into cells bypasses the transferrin-based system and overwhelms the normal regulatory capacity of the cell for iron. 7, 16 Consequently, NTBI entering the cell is not bound to ferritin but becomes weakly bound as low-molecular-weight complexes and subsequently undergoes redox cycling of iron. 55 This not only produces free radicals but also leads to the irreversible precipitation of iron in the form of hemosiderin. 55 Indeed, it is known that very little, if any, of the NTBI that accumulates in cardiac myocytes under conditions similar to those in our experiments is transported back out of the cell unless the cell is treated with iron chelators, 19, 56 suggesting that Fe 2ϩ that enters the cell under these conditions is effectively trapped.
If L-type Ca 2ϩ channels contribute to iron uptake in heart, it is reasonable to ask whether this uptake pathway can account for the iron levels observed clinically. Patients with secondary hemochromatosis often have total serum iron levels of 20 to 61 mol/L, with estimated NTBI of Ϸ1 to 20 mol/L. 26 -28 Under these conditions, the amount of iron accumulation predicted to occur via the L-type Ca 2ϩ channels in 10 to 15 years, a relevant period for patients not receiving chelation therapy, 14 would be 3 to 5 mg of iron per gram of heart. This compares favorably with the 2 to 8 mg of iron per gram of heart typically observed in these patients. 19, 57 The Fe 2ϩ -mediated slowing of Ca 2ϩ current inactivation in our studies is analogous to the slowing of Ca 2ϩ current inactivation by Ba 2ϩ after Ca 2ϩ permeates the channel pore. 45, 46, 58 45, 46 It is, nevertheless, also conceivable that these effects could result from Fe 2ϩ uptake via an independent yet unidentified transporter. But this seems somewhat unlikely because previous single-channel studies have established that the transporter would need to be localized in very close proximity to the Ca 2ϩ channel 58 in order to explain our observations. Alternatively, slowed inactivation by Fe 2ϩ might also be due to irreversible oxidation of the channel as a result of free radical production or sulfhydryl oxidation as reported previously. 59, 60 However, the observed effects of Fe 2ϩ on current inactivation rapidly reversed following washout, which is inconsistent with an oxidation-based mechanism because reversal requires the application of free radical scavengers or sulfhydryl reducing agents. 59, 60 The Fe 2ϩ -induced slowing of Ca 2ϩ current inactivation could have a number of important consequences. For example, the slowing of current decay by 500 mol/L Fe 2ϩ resulted in a 50% increase in the time integral of the Ca 2ϩ current and thus net Ca 2ϩ influx. This is expected to significantly increase intracellular Ca 2ϩ levels 61 and possibly contribute to contractile dysfunction (Ca 2ϩ overload) or impaired diastolic function observed during the early stages of iron overload. 7 On the other hand, slowed inactivation of L-type Ca 2ϩ currents would increase NTBI Fe 2ϩ entry into the myocytes, which may explain the upregulation of Fe 2ϩ uptake that was previously reported to occur in iron-loaded cardiac myocytes. 19, 25 In summary, our data supports the hypothesis that NTBI uptake and iron accumulation by myocardium occurs via L-type Ca 2ϩ channels. Consistent with this assertion, we have recently observed a 2-fold reduction in myocardial iron content and mortality with L-type Ca 2ϩ channel blockers amlodipine and verapamil using an in vivo murine model of cardiac iron overload (G.Y.O. and P.H.B., unpublished data, 1998). Poor patient compliance with deferoxamine treatment 14 and the lack of efficacy with the oral iron chelator, deferiprone, 15 warrants the development of alternative strategies for the treatment of iron overload cardiomyopathies.
Our results suggest that inhibition of Fe 2ϩ uptake by Ca 2ϩ channel blockers might be useful for the clinical management of iron overload disorders. Finally, our observations could also be of significance in other tissues, such as pancreas and pituitary glands, which also possess high L-type Ca 2ϩ channel activity 62, 63 for hormone secretion, because iron overload is commonly associated with both diabetes and pituitary hormone dysfunction. 4, 5, 7 
